Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

5/1/24 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNDX alert in real time by email

WALTHAM, Mass., May 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 8, 2024.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Wednesday, May 8, 2024 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax1Q24

Domestic Dial-in Number: 800-590-8290

International Dial-in Number: 240-690-8800

Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX1Q24.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contact

Sharon Klahre

Syndax Pharmaceuticals, Inc.

[email protected]

Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-first-quarter-2024-financial-results-and-host-conference-call-and-webcast-on-may-8-2024-302132752.html

SOURCE Syndax Pharmaceuticals, Inc.

Get the next $SNDX alert in real time by email

Recent Analyst Ratings for

$SNDX

Date	Price Target	Rating	Analyst
10/24/2024	$37.00	Buy	UBS
6/28/2024	$37.00	Buy	Jefferies
1/31/2024	$36.00 → $23.00	Sector Outperform → Sector Perform	Scotiabank
12/22/2023	$45.00	Buy	Mizuho
10/25/2023	$29.00	Buy	BofA Securities
10/11/2023	$30.00	Buy	Goldman
7/27/2023		Sector Outperform	Scotiabank
7/11/2023	$40.00	Buy	Guggenheim

More analyst ratings

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

Chat with this insight

Recent Analyst Ratings for $SNDX

$SNDX Press Releases

Fastest customizable press release news feed in the world

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

$SNDX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

$SNDX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Goldan Keith A. bought $25,037 worth of shares (1,250 units at $20.03), increasing direct ownership by 2% to 52,623 units (SEC Form 4)

$SNDX Market Insights

Live Market Insights

Jefferies Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $37

Stifel Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $42

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target

$SNDX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

UBS initiated coverage on Syndax Pharmaceuticals with a new price target

Jefferies initiated coverage on Syndax Pharmaceuticals with a new price target

Syndax Pharmaceuticals downgraded by Scotiabank with a new price target

$SNDX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

$SNDX Financials

Live finance-specific insights

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

$SNDX Leadership Updates

Live Leadership Updates

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

$SNDX SEC Filings

Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$SNDX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Goldan Keith A. bought $25,037 worth of shares (1,250 units at $20.03), increasing direct ownership by 2% to 52,623 units (SEC Form 4)

SEC Form 4 filed by Rizo Aleksandra

SEC Form 3 filed by new insider Rizo Aleksandra

Recent Analyst Ratings for
$SNDX

$SNDX
Press Releases

$SNDX
FDA approvals

$SNDX
Insider Purchases

$SNDX
Market Insights

$SNDX
Analyst Ratings

$SNDX
Large Ownership Changes

$SNDX
Financials

$SNDX
Leadership Updates

$SNDX
SEC Filings

$SNDX
Insider Trading